Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668130 | 1.00 | P2RY12 (0.43) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| Hydrochloric Acid SCHEMBL23668150 | 0.99 | P2RY12 (0.42) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| Hydrochloric Acid SCHEMBL23668149 | 0.99 | P2RY12 (0.42) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| SCHEMBL23668164 | 0.91 | P2RY12 (0.42) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| SCHEMBL21808183 | 0.91 | P2RY12 (0.42) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| Hydrochloric Acid SCHEMBL23668159 | 0.90 | P2RY12 (0.41) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| Hydrochloric Acid SCHEMBL21808316 | 0.90 | P2RY12 (0.41) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| SCHEMBL23668162 | 0.88 | ALDH1A1 (0.44) | P2RY12GAANTRK1CYP1A2MAPK1 | |
| SCHEMBL23668142 | 0.88 | P2RY12 (0.43) | P2RY12GAANTRK1TSHRKMT2A | |
| SCHEMBL23668144 | 0.88 | P2RY12 (0.43) | P2RY12GAANTRK1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | J2H BIOTECH INC. (KR) | 2022-08-30 | — | — | US | claimed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | claimed |
| EP-3854787-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | J2H Biotech Inc. (KR) | 2021-07-28 | — | — | EP | claimed |
| CN-112714760-A | Edaravone prodrug compound and medical application thereof in treating or improving neurodegenerative or motor neuron diseases | J2H生物科技有限公司 | 2021-04-27 | — | — | CN | claimed |
| WO-2020060092-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | 제이투에이치바이오텍 주식회사 | 2020-03-26 | — | — | WO | claimed |
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | J2H BIOTECH INC. (KR) | 2022-08-30 | — | — | US | disclosed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | disclosed |
| EP-3854787-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | J2H Biotech Inc. (KR) | 2021-07-28 | — | — | EP | disclosed |
| CN-112714760-A | Edaravone prodrug compound and medical application thereof in treating or improving neurodegenerative or motor neuron diseases | J2H生物科技有限公司 | 2021-04-27 | — | — | CN | disclosed |
| WO-2020060092-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | 제이투에이치바이오텍 주식회사 | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | SMN1; SMN2, NLN, EDNRA | P2RY12 1560/4885GAA 37/4885NTRK1 1439/4885 |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | SMN1; SMN2, NLN, EDNRA | P2RY12 1560/4885GAA 37/4885NTRK1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.